Aevi Genomic Medicine (GNMX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2012 | 12-2011 | 09-2011 | 06-2011 | 03-2011 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -2,712 | -8,096 | -6,085 | -2,661 | -338 |
| Depreciation Amortization | 35 | 98 | 65 | 36 | 17 |
| Accounts receivable | -727 | 533 | 357 | 629 | -26 |
| Accounts payable and accrued liabilities | -6 | 764 | 789 | 126 | 275 |
| Other Working Capital | -743 | 1,208 | 1,405 | 873 | 340 |
| Other Operating Activity | 1,791 | -2,534 | -1,988 | -2,000 | -1,800 |
| Operating Cash Flow | $-2,362 | $-8,027 | $-5,457 | $-2,997 | $-1,532 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -36 | -289 | -250 | -171 | -45 |
| Other Investing Activity | -4 | 0 | -9 | -2 | 0 |
| Investing Cash Flow | $-40 | $-289 | $-259 | $-173 | $-45 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | N/A | N/A | N/A | 26 |
| Common Stock Issued | N/A | 10,452 | 10,427 | 10,427 | 38 |
| Financing Cash Flow | $N/A | $10,452 | $10,427 | $10,427 | $64 |
| Beginning Cash Position | 4,995 | 2,859 | 2,859 | 2,859 | 2,859 |
| End Cash Position | 2,593 | 4,995 | 7,570 | 10,116 | 1,346 |
| Net Cash Flow | $-2,402 | $2,136 | $4,711 | $7,257 | $-1,513 |
| Free Cash Flow | |||||
| Operating Cash Flow | -2,362 | -8,027 | -5,457 | -2,997 | -1,532 |
| Capital Expenditure | -36 | -289 | -250 | -171 | -45 |
| Free Cash Flow | -2,398 | -8,316 | -5,707 | -3,168 | -1,577 |